AUTHOREA
Log in Sign Up Browse Preprints
Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Title : ALL relapse after anti-CD19 CAR-T cells therapy in a young patient: which therapeutic options ?
  • +4
  • Audrey Grain,
  • Jocelyn Ollier,
  • Thierry Guillaume,
  • Patrice Chevallier,
  • Baptiste Le Calvez,
  • Marion Eveillard,
  • Béatrice Clémenceau
Audrey Grain
ERL Centre de Cancerologie et d'Immunologie Nantes-Angers

Corresponding Author:[email protected]

Author Profile
Jocelyn Ollier
ERL Centre de Cancerologie et d'Immunologie Nantes-Angers
Author Profile
Thierry Guillaume
Centre Hospitalier Universitaire de Nantes
Author Profile
Patrice Chevallier
Centre Hospitalier Universitaire de Nantes
Author Profile
Baptiste Le Calvez
Centre Hospitalier Universitaire de Nantes
Author Profile
Marion Eveillard
Centre Hospitalier Universitaire de Nantes
Author Profile
Béatrice Clémenceau
ERL Centre de Cancerologie et d'Immunologie Nantes-Angers
Author Profile

Abstract

Therapeutic options in B-acute lymphoblastic leukemia (ALL) relapses after anti-CD19 CAR-T cells are still debated. Here, we analysed leukemic cells of a young patient who had several CD19+ relapses of B-ALL after hematopoietic stem cells transplant (HSCT) and after anti-CD19 CAR-T cells (tisagenlecleucel). Extensive membrane immunophenotype revealed the appearance of new targets. Lysis sensibility analysis performed by 51Cr release and long term killing assays revealed the in vitro persistence of sensitivity to cytolytic activity of CAR-T cells. An immunosuppressive monocytic population was identified in the last relapse sample. Mechanisms leading to ALL resistance are analysed and therapeutic options are discussed.